Human Anti-Dengue Virus IgG ELISA Kit

R&D Systems | Catalog # DENG00

R&D Systems
Discontinued Product
DENG00 has been discontinued. View all Dengue Virus IgG products.

Key Product Details

Species

Human

Conjugate

HRP

Product Summary for Human Anti-Dengue Virus IgG ELISA Kit

Kit Summary

The Human Anti-Dengue Virus IgG ELISA Kit is a 3.5 hour solid phase ELISA designed to measure Dengue Virus IgG antibodies in human serum and EDTA plasma.

Key Benefits

  • High specificity with minimal cross-reactivity with Zika Virus IgG antibodies
  • High sensitivity
  • Detection of Dengue Virus IgG antibodies later in the infection when IgM antibodies may be undetectable

RT-PCR detects Zika viral RNA in serum during the acute phase of infection. Aedes Aegypti Mosquito

 
Principle of the Assay
Aedes Aegypti Mosquito

This is an antigen-down enzyme immunoassay where recombinant Dengue Virus strains 1, 2, 3, & 4 NS1 antigens are pre-coated onto a 96-well microplate and used to bind antibodies found in the sample. When the sample is added (such as human serum or EDTA plasma), antibodies found in the sample that recognize Dengue Virus NS1 antigens bind the antigen coated plate and are retained in the well. After washing away unbound substances, an enzyme linked polyclonal antibody specific for human IgG is added to the wells. Following a wash to remove any unbound enzyme linked antibody, a substrate is added to the wells and color develops in proportion to the amount of IgG antibodies in the sample bound to the Dengue Virus NS1 antigens. The color development is stopped, and the intensity of the color is measured.

The potential for false positives due to Dengue Virus NS1 antigen cross-reactive antibodies to related flaviviruses, such as Zika Virus, is minimized by treatment of the samples. Samples are treated with a propriety treatment reagent prior to being added to the Dengue Virus NS1 antigen coated plate. Sample specific background is determined by adding identically treated samples to an uncoated background plate and measuring the amount of IgG antibodies non-specifically bound to the well. To interpret results, net sample OD readings are calculated by subtracting each sample background plate reading from the Dengue Virus NS1 antigen plate reading.

 

Precision

Intra-Assay Precision (Precision within an assay)

Three Anti-Dengue Virus IgG positive samples with low, middle, and high net O.D. were tested twenty-four times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays)

Three Anti-Dengue Virus IgG positive samples with low, middle, and high net O.D. were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians.

  Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 24 24 24 20 20 20
Net O.D. 0.838 1.776 2.811 0.709 1.556 2.756
Standard deviation 0.019 0.033 0.039 0.079 0.151 0.276
CV (%) 2.3 1.9 1.4 11.1 9.7 10

Specificity

This assay recognizes Dengue Virus specific human IgG antibodies with minimal cross-reactivity of human Zika IgG antibodies.

Background: Dengue virus

Dengue fever is a mosquito-borne tropical disease caused by the Dengue Virus (DENV), a member of the flavivirus genus. Symptoms of Dengue fever include a high fever, headache, vomiting, muscle and joint pains and a characteristic skin rash. In a small proportion of cases, the disease develops into the life-threatening Dengue hemorrhagic fever, which results in bleeding, low levels of blood platelets and blood plasma leakage, or into Dengue shock syndrome, where dangerously low blood pressure occurs (1). The incidence of Dengue Virus infections has grown dramatically around the world in recent decades. The actual numbers of Dengue cases are underreported, and many cases are misclassified. One recent estimate indicates 390 million Dengue infections per year of which 96 million manifest a level of disease severity (2). Serological diagnosis of Dengue infection is complicated by cross-reactivity among other flaviviruses, such as Zika Virus (ZIKV) (3). Because DENV, ZIKV, and other flavivirus co-circulate in endemic regions and share high sequence similarity, there is a high possibility of IgM and IgG cross-reactivity in immunoassays (4). There is a need for a simple serological test that displays high Dengue specificity with minimal cross-reactivity with other flaviviruses.

References:
  1. Kularatne, S.A. (2015) BMJ, 351:h4661.
  2. Bhatt, S. et al. (2013) Nature, 496:504.
  3. Musso, D. et al. (2016) Clin. Microbiol. Rev. 29:487.
  4. Cabral-Castro, M.J. et al. (2016) J. Clin. Virol. 82:108.

Formulation, Preparation, and Storage

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Storage

Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Dengue Virus IgG

Dengue virus is a single -stranded, positive-sense RNA virus belonging to the Flavivirdae family and is the causative agent of Dengue fever (1-3). Other viruses in the same family include Japanese encephalitis virus, West Nile virus, and yellow fever (2,3). The Dengue virus is primarily transmitted through Aedes mosquito bites, with 100-400 million people infected annually and approximately 20,000 deaths worldwide per year (1,3). There are four known Dengue virus serotypes (DENV 1-4) that share 65% amino acid sequence similarity (1-2). The serotypes can be further classified into genotypes according to geographical distribution (2,3). The structure of the Dengue virus is ~50 nanometers (nm) in diameter, spherical in shape, and consists of an enveloped single-stranded RNA, an icosahedral nucleocapsid core, and a lipid bilayer (1-3). The Dengue virus genome is 11-kilobases (kb) long and has a 5' untranslated region (UTR), an open reading frame (ORF), and a 3' UTR (1,3). The ORF encodes a polyprotein for the translation of the three structural proteins and seven non-structural proteins (1-3). The structural proteins are the capsid (100 amino acids (aa), 12 kilodalton (kDa)), the pre-membrane (166 aa) or membrane (75 aa, 8.2-8.5 kDa), and envelope (495 aa, 53 kDa) (1-3). The nonstructural proteins are NS1 (350 aa, 45 kDa), NS2A (218 aa, 22 kDa), NS2B (130 aa, 14 kDa), NS3 (618 aa, 70 kDa), NS4A (150 aa, 16 kDa), NS4B (245-249 aa, 27 kDa), NS5 (900 aa, 104 kDa) (1-3).

Dengue virus entry into host cells occurs via receptor-mediated endocytosis by receptor molecules including the mannose receptor, heparan sulfate, glycosaminoglycans, and DC-SIGN (1,3). Following attachment, the virus is endocytosed in clathrin-coated vesicles (1,3). Following internalization, clathrin disassembles and endosomal processing occurs, allowing viral fusion, disassembly, and release of viral RNA (1,3). This release results in viral translation and replication, virus assembly and maturation, and eventual exocytosis of the mature virus (1,3). Infection can result in a wide range of clinical symptoms including mild disease such as Dengue fever which is characterized by fever, headache, joint pain, rash, and retro-orbital pain, or severe, life-threatening conditions like Dengue hemorrhagic fever or Dengue shock syndrome which involves vascular permeability and leakage (1-3). Host immune response against infection includes innate immune response via interferon secretion and pro-inflammatory cytokine production, as well as adaptive immune response involving cellular and humoral components like T cell activation and B-cell mediated antibody production (1-3). As far as treatment for Dengue virus infection, there no commercial antiviral agents, though some anti-pyretics and certain phenolic compounds do show promise in treating infection (1-3). However, Resveratol, an antiviral for other Flavivirus, has been shown to directly attack the Dengue virus genome (1). While more work needs to be done, there are some live-attenuated tetravalent Dengue virus vaccine candidates in clinal trials including DENVax and TV003/TV005 (1-3).

References

1. Nanaware N, Banerjee A, Mullick Bagchi S, Bagchi P, Mukherjee A. Dengue Virus Infection: A Tale of Viral Exploitations and Host Responses. Viruses. 2021;13(10):1967. Published 2021 Sep 30. https://doi.org/10.3390/v13101967

2. Harapan H, Michie A, Sasmono RT, Imrie A. Dengue: A Minireview. Viruses. 2020;12(8):829. Published 2020 Jul 30. https://doi.org/10.3390/v12080829

3. Roy SK, Bhattacharjee S. Dengue virus: epidemiology, biology, and disease aetiology. Can J Microbiol. 2021;67(10):687-702. https://doi.org/10.1139/cjm-2020-0572

Alternate Names

DENV IgG, DENV-IgG

Product Documents for Human Anti-Dengue Virus IgG ELISA Kit

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human Anti-Dengue Virus IgG ELISA Kit

For research use only

Related Research Areas

Infectious Diseases

Customer Reviews for Human Anti-Dengue Virus IgG ELISA Kit

There are currently no reviews for this product. Be the first to review Human Anti-Dengue Virus IgG ELISA Kit and earn rewards!

Have you used Human Anti-Dengue Virus IgG ELISA Kit?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

FAQs for Human Anti-Dengue Virus IgG ELISA Kit

Showing  1 - 5 of 7 FAQs Showing All

  • Q: Can the Human Anti-Dengue Virus IgG ELISA Kit be used for diagnostic purposes?

    A: No, it is not approved for diagnostic use.  The Human Dengue Virus IgG ELISA Kit is for Research Use Only. 

  • Q: Does the kit contain live Virus?

    A: Purified Dengue Virus or other Flaviviruses are not components in the kit.  Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1 & HIV 2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious. 

  • Q: Does this Human Anti-Dengue Virus IgG ELISA Kit show cross-reaction to Zika, West Nile, Yellow Fever, etc.?

    A: Sample treatment minimizes cross reaction to Zika Virus.  Cross-reaction with other Flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested

  • Q: What is the advantage of the Human Anti-Dengue Virus IgG ELISA Kit when compared to PCR?

    A: The viral load of Dengue Virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness. Our Human Anti-Dengue Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Dengue Virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.

  • Q: What is the formulation of the Treatment Reagent in Catalog # DENG00, Human Anti-Dengue Virus IgG ELISA Kit?

    A: This is a propriety formulation designed to reduce cross-reactivity caused by IgG antibodies to Zika, West Nile, Yellow Fever, and other related Flavivirus.

  • Q: What would cause the Calculated Net O.D. Value for the Treatment Control to be greater than 0.170?

    A: The Treatment Control is a Flavivirus antibody control for cross-reactivity.  A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.

  • Q: Why are the background OD readings high with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit?

    A: It is normal to see high background OD readings with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit. It is not known why this is observed. This is one reason specific background OD readings are determined for each patient sample in each assay, which is a unique feature, to this kit to reduce the likelihood of false positives from high background.

  • Q: Can the Human Anti-Dengue Virus IgG ELISA Kit be used for diagnostic purposes?

    A: No, it is not approved for diagnostic use.  The Human Dengue Virus IgG ELISA Kit is for Research Use Only. 

  • Q: Does the kit contain live Virus?

    A: Purified Dengue Virus or other Flaviviruses are not components in the kit.  Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1 & HIV 2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious. 

  • Q: Does this Human Anti-Dengue Virus IgG ELISA Kit show cross-reaction to Zika, West Nile, Yellow Fever, etc.?

    A: Sample treatment minimizes cross reaction to Zika Virus.  Cross-reaction with other Flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested

  • Q: What is the advantage of the Human Anti-Dengue Virus IgG ELISA Kit when compared to PCR?

    A: The viral load of Dengue Virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness. Our Human Anti-Dengue Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Dengue Virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.

  • Q: What is the formulation of the Treatment Reagent in Catalog # DENG00, Human Anti-Dengue Virus IgG ELISA Kit?

    A: This is a propriety formulation designed to reduce cross-reactivity caused by IgG antibodies to Zika, West Nile, Yellow Fever, and other related Flavivirus.

  • Q: What would cause the Calculated Net O.D. Value for the Treatment Control to be greater than 0.170?

    A: The Treatment Control is a Flavivirus antibody control for cross-reactivity.  A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.

  • Q: Why are the background OD readings high with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit?

    A: It is normal to see high background OD readings with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit. It is not known why this is observed. This is one reason specific background OD readings are determined for each patient sample in each assay, which is a unique feature, to this kit to reduce the likelihood of false positives from high background.

  • Q: Can the Human Anti-Dengue Virus IgG ELISA Kit be used for diagnostic purposes?

    A: No, it is not approved for diagnostic use.  The Human Dengue Virus IgG ELISA Kit is for Research Use Only. 

  • Q: Does the kit contain live Virus?

    A: Purified Dengue Virus or other Flaviviruses are not components in the kit.  Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1 & HIV 2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious. 

  • Q: Does this Human Anti-Dengue Virus IgG ELISA Kit show cross-reaction to Zika, West Nile, Yellow Fever, etc.?

    A: Sample treatment minimizes cross reaction to Zika Virus.  Cross-reaction with other Flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested

  • Q: What is the advantage of the Human Anti-Dengue Virus IgG ELISA Kit when compared to PCR?

    A: The viral load of Dengue Virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness. Our Human Anti-Dengue Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Dengue Virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.

  • Q: What is the formulation of the Treatment Reagent in Catalog # DENG00, Human Anti-Dengue Virus IgG ELISA Kit?

    A: This is a propriety formulation designed to reduce cross-reactivity caused by IgG antibodies to Zika, West Nile, Yellow Fever, and other related Flavivirus.

  • Q: What would cause the Calculated Net O.D. Value for the Treatment Control to be greater than 0.170?

    A: The Treatment Control is a Flavivirus antibody control for cross-reactivity.  A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.

  • Q: Why are the background OD readings high with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit?

    A: It is normal to see high background OD readings with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit. It is not known why this is observed. This is one reason specific background OD readings are determined for each patient sample in each assay, which is a unique feature, to this kit to reduce the likelihood of false positives from high background.

  • Q: Can the Human Anti-Dengue Virus IgG ELISA Kit be used for diagnostic purposes?

    A: No, it is not approved for diagnostic use.  The Human Dengue Virus IgG ELISA Kit is for Research Use Only. 

  • Q: Does the kit contain live Virus?

    A: Purified Dengue Virus or other Flaviviruses are not components in the kit.  Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1 & HIV 2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious. 

  • Q: Does this Human Anti-Dengue Virus IgG ELISA Kit show cross-reaction to Zika, West Nile, Yellow Fever, etc.?

    A: Sample treatment minimizes cross reaction to Zika Virus.  Cross-reaction with other Flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested

  • Q: What is the advantage of the Human Anti-Dengue Virus IgG ELISA Kit when compared to PCR?

    A: The viral load of Dengue Virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness. Our Human Anti-Dengue Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Dengue Virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.

  • Q: What is the formulation of the Treatment Reagent in Catalog # DENG00, Human Anti-Dengue Virus IgG ELISA Kit?

    A: This is a propriety formulation designed to reduce cross-reactivity caused by IgG antibodies to Zika, West Nile, Yellow Fever, and other related Flavivirus.

  • Q: What would cause the Calculated Net O.D. Value for the Treatment Control to be greater than 0.170?

    A: The Treatment Control is a Flavivirus antibody control for cross-reactivity.  A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.

  • Q: Why are the background OD readings high with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit?

    A: It is normal to see high background OD readings with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit. It is not known why this is observed. This is one reason specific background OD readings are determined for each patient sample in each assay, which is a unique feature, to this kit to reduce the likelihood of false positives from high background.

  • Q: Can the Human Anti-Dengue Virus IgG ELISA Kit be used for diagnostic purposes?

    A: No, it is not approved for diagnostic use.  The Human Dengue Virus IgG ELISA Kit is for Research Use Only. 

  • Q: Does the kit contain live Virus?

    A: Purified Dengue Virus or other Flaviviruses are not components in the kit.  Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1 & HIV 2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious. 

  • Q: Does this Human Anti-Dengue Virus IgG ELISA Kit show cross-reaction to Zika, West Nile, Yellow Fever, etc.?

    A: Sample treatment minimizes cross reaction to Zika Virus.  Cross-reaction with other Flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested

  • Q: What is the advantage of the Human Anti-Dengue Virus IgG ELISA Kit when compared to PCR?

    A: The viral load of Dengue Virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness. Our Human Anti-Dengue Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Dengue Virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.

  • Q: What is the formulation of the Treatment Reagent in Catalog # DENG00, Human Anti-Dengue Virus IgG ELISA Kit?

    A: This is a propriety formulation designed to reduce cross-reactivity caused by IgG antibodies to Zika, West Nile, Yellow Fever, and other related Flavivirus.

  • Q: What would cause the Calculated Net O.D. Value for the Treatment Control to be greater than 0.170?

    A: The Treatment Control is a Flavivirus antibody control for cross-reactivity.  A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.

  • Q: Why are the background OD readings high with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit?

    A: It is normal to see high background OD readings with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit. It is not known why this is observed. This is one reason specific background OD readings are determined for each patient sample in each assay, which is a unique feature, to this kit to reduce the likelihood of false positives from high background.

  • Q: Can the Human Anti-Dengue Virus IgG ELISA Kit be used for diagnostic purposes?

    A: No, it is not approved for diagnostic use.  The Human Dengue Virus IgG ELISA Kit is for Research Use Only. 

  • Q: Does the kit contain live Virus?

    A: Purified Dengue Virus or other Flaviviruses are not components in the kit.  Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1 & HIV 2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious. 

  • Q: Does this Human Anti-Dengue Virus IgG ELISA Kit show cross-reaction to Zika, West Nile, Yellow Fever, etc.?

    A: Sample treatment minimizes cross reaction to Zika Virus.  Cross-reaction with other Flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested

  • Q: What is the advantage of the Human Anti-Dengue Virus IgG ELISA Kit when compared to PCR?

    A: The viral load of Dengue Virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness. Our Human Anti-Dengue Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Dengue Virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.

  • Q: What is the formulation of the Treatment Reagent in Catalog # DENG00, Human Anti-Dengue Virus IgG ELISA Kit?

    A: This is a propriety formulation designed to reduce cross-reactivity caused by IgG antibodies to Zika, West Nile, Yellow Fever, and other related Flavivirus.

  • Q: What would cause the Calculated Net O.D. Value for the Treatment Control to be greater than 0.170?

    A: The Treatment Control is a Flavivirus antibody control for cross-reactivity.  A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.

  • Q: Why are the background OD readings high with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit?

    A: It is normal to see high background OD readings with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit. It is not known why this is observed. This is one reason specific background OD readings are determined for each patient sample in each assay, which is a unique feature, to this kit to reduce the likelihood of false positives from high background.

  • Q: Can the Human Anti-Dengue Virus IgG ELISA Kit be used for diagnostic purposes?

    A: No, it is not approved for diagnostic use.  The Human Dengue Virus IgG ELISA Kit is for Research Use Only. 

  • Q: Does the kit contain live Virus?

    A: Purified Dengue Virus or other Flaviviruses are not components in the kit.  Some components in this kit contain human source materials and have been tested negative for antibodies to HIV 1 & HIV 2, Hepatitis C and Hepatitis B surface antigen. However, material should be handled as potentially infectious. 

  • Q: Does this Human Anti-Dengue Virus IgG ELISA Kit show cross-reaction to Zika, West Nile, Yellow Fever, etc.?

    A: Sample treatment minimizes cross reaction to Zika Virus.  Cross-reaction with other Flavivirus such as West Nile or Yellow Fever is likely to be minimal, however has not been fully tested

  • Q: What is the advantage of the Human Anti-Dengue Virus IgG ELISA Kit when compared to PCR?

    A: The viral load of Dengue Virus can be of low intensity and short duration, so detection via real-time RT-PCR has a very limited timeframe, and typically should be performed early (up to 10 days) after onset of illness. Our Human Anti-Dengue Virus IgG ELISA Kit can detect neutralizing IgG antibodies to Dengue Virus as early as 5 days after the onset of illness, and the IgG antibodies formed as immune response are expected to persist for many years, possibly lifelong, after infection.

  • Q: What is the formulation of the Treatment Reagent in Catalog # DENG00, Human Anti-Dengue Virus IgG ELISA Kit?

    A: This is a propriety formulation designed to reduce cross-reactivity caused by IgG antibodies to Zika, West Nile, Yellow Fever, and other related Flavivirus.

  • Q: What would cause the Calculated Net O.D. Value for the Treatment Control to be greater than 0.170?

    A: The Treatment Control is a Flavivirus antibody control for cross-reactivity.  A high reading may indicate error in preparation of the Treatment Control, or the Treatment Reagent is expired.

  • Q: Why are the background OD readings high with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit?

    A: It is normal to see high background OD readings with some patient samples when using the Human Anti-Dengue Virus IgG ELISA kit. It is not known why this is observed. This is one reason specific background OD readings are determined for each patient sample in each assay, which is a unique feature, to this kit to reduce the likelihood of false positives from high background.

Showing  1 - 5 of 7 FAQs Showing All
View all FAQs for ELISA Kits